Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alcon Inc. Ordinary Shares (NY:ALC)

73.88 -0.01 (-0.01%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Alcon Publishes Agenda for 2024 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Alcon Inc. (NYSE: ALC) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
From Alcon Inc. Corporate
Via Business Wire
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
From Alcon Inc. Investors
Via Business Wire
What 6 Analyst Ratings Have To Say About Alcon
 
Via Benzinga
The Latest Analyst Ratings for Alcon
 
Via Benzinga
Why Medical Device Company Alcon Shares Are Sliding Today
Alcon Inc (NYSE: ALC) shares are trading lower by around 5%  
Via Benzinga
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month
"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins... 
Via Benzinga
Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: 'Innovation Is Key'
Innovation and digitalization have been in focus among ophthalmology majors. 
Via Benzinga
Good News For Dry Eye Disease Patients: Eye Care Focused Alcon's Treatment Shows Encouraging Benefit In Late-Stage Trials
Alcon (NYSE: ALC) released topline results from the two Phase 3 trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of  
Via Benzinga
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
From Alcon Inc. Investors
Via Business Wire
Where Alcon Stands With Analysts
 
Via Benzinga
Alcon Inc. (NYSE: ALC) Highlighted for Surprising Price Action
Via Investor Brand Network
Where Alcon Stands With Analysts
 
Via Benzinga
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
From Lifecore Biomedical, Inc.
Via GlobeNewswire
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
From Alcon Inc. Investors
Via Business Wire
Intel To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
US Stocks On Track To Build On Gains As Traders Await A Batch Of Data; Can Market Resist Profit Taking?
U.S. stocks could build on the momentum they picked up on Tuesday following the release of benign inflation data. Traders get to digest another batch of economic data on producer price inflation,... 
Via Benzinga
Topics Economy
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. 
Via Benzinga
Varex Imaging Reports Weak Sales, Joins Alcon, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning on Wednesday, with the Dow Jones futures gaining more than 90 points this morning. 
Via Benzinga
Topics Stocks
Alcon Reports Third Quarter 2023 Results
From Alcon Inc. Investors
Via Business Wire
Alcon Gears Up For Q3 Print; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts
Alcon Inc. (NYSE: ALC) is projected to release financial results for its third quarter, after the closing bell on Nov. 14, 2023. 
Via Benzinga
Alcon Showcases Cloud-based Planning and World-class Digital Technologies During AAO 2023
From Alcon Inc. Investors
Via Business Wire
Alcon Launches TOTAL30 Multifocal Contact Lenses for Patients with Presbyopia
From Alcon Inc. Investors
Via Business Wire
Cataract Surgery with Alcon’s AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence
From Alcon Inc. Corporate
Via Business Wire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
Alcon Announces its Largest-Ever Scientific Program at the 41st Congress of the ESCRS, Showcasing New Data and Innovation to Support Ophthalmic Surgical Teams
From Alcon Inc. Corporate
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 17, 2023
 
Via Benzinga
NVIDIA To Rally Around 84%? Here Are 10 Other Analyst Forecasts For Thursday
BMO Capital lowered the price target for Target Corporation (NYSE: TGT) from $140 to $130. BMO Capital analyst Kelly Bania maintained a Market Perform rating. Target shares gained 0.3% to $129.10 in... 
Via Benzinga
Alcon Reports Second Quarter 2023 Results
From Alcon Inc. Investors
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.